Johnson & Johnson (JNJ) Tops Q4 EPS by 4c, Offers FY21 Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Anthropic and Accenture partner on embedded AI safety evaluation
Johnson & Johnson (JNJ) PT Raised to $193 at Credit Suisse
January 27, 2021 7:51 AM ESTCredit Suisse analyst Matt Miksic raised the price target on Johnson & Johnson (NYSE: JNJ) to $193.00 (from $168.00) while maintaining a Outperform rating following the company's 4Q earnings report. JNJs Med Devices results were in line with expectations of a late-Q4 slowdown in elective procedures, consistent... More
